Ibrutinib is used for the treatment of blood cancers like mantle cell lymphoma, chronic lymphocytic leukemia (CLL), and lymphoplasmacytic lymphoma.
🛒 How to order this item?
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
Ibrucent 140mg Capsule is employed for the treatment of various conditions:
There is limited information on the interaction of Ibrucent 140mg Capsule with alcohol.
Due to limited information about its safety during pregnancy, Ibrucent 140mg Capsule is not recommended for use by pregnant women to avoid potential risks to the developing fetus.
There's no available information on whether Ibrucent 140mg Capsule passes into breast milk. Breastfeeding women are advised not to use this medication.
Ibrucent 140mg Capsule might have a slight impact on driving ability. If you experience dizziness or weakness after taking the medicine, it's recommended to avoid driving.
Patients with kidney diseases should use Ibrucent 140mg Capsule with caution due to the increased risk of worsening their condition. Close monitoring of kidney function and potential dose adjustments might be necessary based on the patient's clinical situation.
Patients with liver diseases should also use Ibrucent 140mg Capsule with caution, as it could worsen their condition. Regular monitoring of liver function is important, and dose adjustments or alternative treatments might be required based on the patient's clinical condition.
Ibrucent 140mg Capsule works by inhibiting the actions of certain abnormal proteins that cause the cancer cells to multiply. This helps in stopping the growth and spread of cancer.
Possible adverse reactions include bleeding, infections, atrial fibrillation, hypertension, and more. Diarrhea and visual disturbances are also noted.
Ibrutinib is prescribed for various conditions:
Ibrutinib, a BTK inhibitor, disrupts B-cell antigen receptor and cytokine receptor pathways. This inhibits malignant B-cell growth, survival, and migration.
For MCL and MZL: 560 mg daily until disease progression or unacceptable toxicity. For CLL/SLL and WM: 420 mg daily until disease progression or unacceptable toxicity. In combination with bendamustine and rituximab: 420 mg daily.
Administration
Take orally daily at a consistent time, swallowing capsules whole with water.
Ibrutinib may interact with certain medications like ketoconazole, clarithromycin, and others. Consult your doctor regarding potential interactions.
Avoid if hypersensitive to active ingredients or excipients.
Ibrutinib can harm a developing fetus. Pregnant or breastfeeding individuals should avoid it.
Make sure to discuss with your doctor if:
Store below 30°C, away from light, and out of children's reach.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.